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RCarotid Intima-Media
Thickness Progression and
Cardiovascular Disease Risk
Costanzo et al. (1) concluded that slowed progression of carotid
intima-media thickness (CIMT) with drug therapies does not
predict reduced cardiovascular disease (CVD) risk. Unfortunately,
their analytical technique, meta-regression, is not suitable for
evaluating this relationship. The limitations of meta-regression are
well-known (2). Major pitfalls of their study include the following:
1. CIMT is not a standardized technology. Their meta-regression
included studies with different imaging and measurement
techniques. By grouping them, the authors created a null bias.
Furthermore, some laboratories have highly reproducible tech-
niques and excellent quality assurance procedures. Those labo-
ratories have reliably reported strong relationships between
changes in CVD risk factors, changes in CIMT, and CVD risk.
But, some laboratories have poor measurement accuracy and
reproducibility. Because the meta-regression lumped widely
differing methodologies together, it is no surprise that they did
not find a relationship among all the noise from the individual
trials. Adjusting for the year of the study, the authors’ proposed
solution, does not address this problem.
2. Short follow-up duration. CIMT progression studies are ex-
periments that evaluate one biological effect of an interven-
tion—change in carotid atherosclerosis burden (or more pre-
cisely, change in wall thickness, a measure of arterial injury).
CIMT progression studies are performed to obtain information
about the effect of an intervention on the arterial wall in a
shorter time period than usually is needed to observe differences
in CVD event rates. The short-term events analyzed by the
authors may not reflect the anatomic substrate measured by
CIMT testing, because short-term events are more related to
inflammation and thrombosis than atherosclerosis burden. Pro-
ponents of CIMT imaging as a research tool do not claim that
CIMT changes perfectly reflect CVD risk, especially in the
short term. Their analysis attacks a red herring and faults a
technique for not predicting events that are not mediated by
what it measures. Indeed, the Cholesterol Lowering Athero-
sclerosis Study showed a significant relationship between
CIMT changes and lipid treatment after 2 years, but the
relationships between changes in lipids, CIMT, and CVD
events took many more years to be identified (3,4). The studies
analyzed by Costanzo et al. (1) were, for the most part, only 1
to 2 years in duration.
. The meta-regression was performed on summary data, not data
from individual study participants, and there were a lot of
missing data—especially important considerations given the
small number of CVD events they analyzed relative to the large
number of covariates and studies in their models.No surrogate is perfect, but the vast majority of interventions that
reduce CIMT progression also reduce CVD events. Exceptions
include small, poorly conducted studies or interventions where the
beneficial effect on CIMT was observed in different individuals
than those with increased CVD risk (i.e., hormone replacement
therapy). The limitations of meta-regression, short follow-up
duration, and data limitations explain why the authors did not
observe a relationship between CIMT changes and CVD events. It
is noteworthy that another analysis that focused on high-quality
CIMT studies of statins came to a different conclusion (5).
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Carotid Intima-Media Thickness
as a Surrogate Endpoint
We read with great interest the recently published meta-analysis by
Costanzo et al. (1) investigating whether changes in carotid
intima-media thickness (CIMT) affect major cardiovascular end-
points, including cardiovascular-related and all-cause mortality.
The study was carefully executed and reported that changes in
CIMT in response to drug therapy do not translate into changes in
major cardiovascular events. The analysis adds to the growing
understanding that although surrogate endpoints such as CIMT at
baseline may be correlated with clinical outcomes, changes in these
